

#53
BP
4-13-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul R. Schimmel

Serial No.: 08/249,689

Art Unit: 1631

RECEIVED

Filed: May 26, 1994

Examiner: J. Brusca

APR 11 2002

TECH CENTER 1600/2900

For: *"DESIGNING COMPOUNDS SPECIFICALLY INHIBITING RIBONUCLEIC ACID FUNCTION"*

Assistant Commissioner for Patents
Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. § 1.132

Sir:

I, Julius Rebek, Jr., hereby declare that:

1. I am Director of The Skaggs Institute for Chemical Biology and Professor of Chemistry at The Scripps Research Institute, and hold a Ph.D. in Chemistry from the Massachusetts Institute of Technology. I have over 30 years experience in the field of bioorganic chemistry with an emphasis on molecular recognition and intermolecular forces, and over 15 years experience in the study of nucleic acid recognition. A partial curriculum vitae is attached to this declaration as an exhibit.

2. I have reviewed the specification of the above-identified application, and the claims as filed July 2, 2001.

3. I have reviewed the Office Action mailed January 11, 2002, in connection with the above-identified application.

DECLARATION UNDER 37 C.F.R. § 1.132

4. I understand that claims 11-13, 17-19, and 21 define a compound comprising hydrogen bond donor and acceptor sites arranged to specifically bind and inhibit the function of a targeted RNA molecule, wherein the compound is specifically directed to and binds to a critical region of the RNA molecule, located within the minor groove of the RNA molecule, identified by a combination of the primary, secondary and tertiary structure of the critical region. It is my further understanding that these claims have been rejected on the basis that one skilled in the art in September 1990, would not know the structure or identity of these compounds as defined by the claims, based on the specification and what was known to those skilled in the art at the time. This rejection is referred to as a failure to comply with the written description requirement. I have been advised that to comply with the written description, one must meet the following legal standard:

"....conception of a chemical compound requires that the inventor be able to define it so as to distinguish it from other materials, and to describe how to obtain it. Conception does not occur unless one has a mental picture of the structure of the chemical, or is able to define it by its method of preparation, its physical or chemical properties, or whatever characteristics sufficiently distinguish it."

Amgen, 927 F.2d at 1206, 18 USPQ 2d at 1021. Furthermore the court has stated that in order to satisfy the written description requirement, "the applicant need not describe the subject matter claimed in exact terms. However, the description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed." *Monsanto Co. v. Mycogen Plant Science, Inc.*, 61 F.Supp.2d 133, 188 (D.Del. Aug 18, 1999).

DECLARATION UNDER 37 C.F.R. § 1.132

5. As an expert in the field of molecular recognition, and as an individual with extensive knowledge of the level of understanding of those of skill in the art as of September 1990, I believe that the specification and claims, in view of what was known to those in the art, provides a written description that is sufficient to comply with the legal standard as defined above. I present in this declaration evidence indicating that attractive and repulsive forces present in the critical region of the minor groove of RNA dictate or define the geometrical constraints of the region. These forces, as described in the specification, and below, define the structure of the critical region in a way that provides one with a mental picture of a defined "space" that can only be accessed by a compound of the correct "shape". It will help, perhaps, to view the minor groove as a "lock" and the compound as the "key", wherein the shape of the interior of the lock is defined by hydrophobic, hydrogen bonding, and electrostatic forces provided by nucleic acid bases. The key (compound) will only fit into the lock if it is able to "complement" these forces.

6. RNA usually forms double stranded regions by looping and base pairing complementary, palindromic and/or nearly palindromic sequences. Double stranded helical regions will form the major and minor grooves often used in the geometric descriptions of nucleic acid molecules. RNA geometry may deviate from what is usually defined as Watson-Crick base pairing, which lies at the core of normal DNA helix formation. However, RNA geometries such as symmetrical or asymmetric interior loops, bulge loops, purine-purine mispairs, GU or wobble pairs and pseudoknots (which are tandem stem loops) all retain the

DECLARATION UNDER 37 C.F.R. § 1.132

ability to form major and minor grooves. Such geometrical arrangements provide unique platforms for binding of compounds in the minor groove.

The critical region in the minor groove as described in the specification is sufficient to describe the claimed inhibitory compound. The primary basis for sequence discrimination in RNA is the minor groove. Nucleotide bases and sequences of bases are most accessible to compounds via the minor groove. The minor groove is not only wider, but significantly more shallow than the relatively narrower and deeper groove provided by the major groove. The major groove is too deep and too narrow for sizable molecules to make direct sequence specific contact. The nature of the bases recognized by any particular amino acid side chain or other compound depends upon the local geometry within the minor groove. Factors determining the geometric configuration of the critical region of the minor groove are the hydrophobicity of the local environment, the pattern of accessible hydrogen bond donors and acceptors present, and the repulsive and attractive forces that exist as electrostatic entities within the targeted minor groove.

Hydrophobic Environment of the Minor Groove

Planar aromatic purines and pyrimidines interact strongly to form parallel stacked structures. As stated at page 2, lines 21-29 of the specification, the nucleotide bases of the RNA molecule are planar and perpendicular to the helical axis. Because the RNA helix is in an alpha conformation, the bases and sequences of bases are most accessible from the minor groove. Energetically speaking, such stacked structures are critical in determining the nucleic acid conformation. Stacked structures tend to be maximized in nucleic acids. For example, base stacking occurs in the tRNA structure to almost the maximum conceivable extent.

DECLARATION UNDER 37 C.F.R. § 1.132

A consequence of the extensive stacking and base pairing is that many of the bases are rendered inaccessible to solvent. Inaccessibility to solvent provides for a local hydrophobic and nonaqueous environment. Taken together with the fact that apolar side-chain moieties of amino acids will prefer to reside in an apolar nonaqueous environment, one will realize that the extensive stacking of bases provides an ideal hydrophobic environment for compounds that exhibit apolar-like surfaces to bind. Many of these surfaces will become exposed once initial contact is made with the target RNA (many times this contact will induce a conformational change wherein the binding conformation of the compound is stabilized). An example of a motif in which apolar residues *are exposed* is the RNA Recognition Motif, or RRM, found in many RNA binding proteins. RNA binds on the flat face of a β -sheet in RRM, which carries a number of Arg, Lys and sometimes His residues. Residues such as these provide electrostatic interactions with the RNA backbone. The non-polar aromatic residues are ideally located, exposed on the face of the β -sheet, where they can interact and stack with bases of the RNA.

Hydrogen Bonding

The chemical basis for the discrimination between different base pairs lies in the order of hydrogen bond acceptor and donor groups across the base pair that is accessible to a particular compound. Thus, the compound/base pair specific interaction is part of a network of specific hydrogen bonds. Page 7, lines 24-26, teach this point as it relates to the minor groove. Because there are actually fewer differences in the pattern of potential hydrogen bond donors and acceptors in the minor groove (G:C and A:U), the specific pattern of H-bond acceptors and donors that may be present on a specific inhibitory compound is further limited by the minor

DECLARATION UNDER 37 C.F.R. § 1.132

groove. Single stranded nucleic acid is more flexible and can twist and turn to meet the compound's hydrogen bonding pattern, thereby making it extremely difficult to meet the specificity requirements of the compound. However, those RNA molecules, such as those described above and in the specification, are less flexible because of their formation of secondary structures, such as base pairing. Base paired regions also limit the flexibility in the nearby single stranded regions. Less flexibility will provide opportunity for *specific* interactions via a hydrogen bond network that is static, not in a state of flux.

Electrostatic Interactions

The electrostatic *force* between the compound and the targeted RNA defines the *affinity* of the interaction. The hydrophobic interactions and hydrogen bonds, described above, are short range interactions based on desolvation induced-dipole and molecular dipole moments. Because electrostatic interactions can be sensed several angstroms from the point charge, they are considered to be long range interactions. The strength of these electrostatic interactions is a function of the dielectric property of the local environment. Chemical side groups on the inhibitory compound, provided that they are in the correct spatial location, orientation, and have the correct charge, will increase the strength of these electrostatic interactions. A higher degree of complementarity will strengthen these type of interactions. Such complementarity is achieved via the maximization of hydrogen bonding, hydrophobic interactions, and defining the size of the compound based upon the known dimensions of the targeted minor groove.

Geometric and Steric constraints

DECLARATION UNDER 37 C.F.R. § 1.132

Given that the minor groove of RNA is derived from a combination of double stranded regions of nucleic acid structure, the arrangement of the nucleotide bases of the RNA molecule that are planar and perpendicular to the helical axis, the formation of a hydrophobic core, as well as the hydrogen bonding network present as "acceptors" and "donors", the field of RNA biochemistry realizes that these constraints provide a very defined geometry that is present within the minor groove. While the minor groove is wider and more shallow than its counterpart, the major groove, the minor groove can be defined geometrically and sterically because of the hydrophobic nature, hydrogen bonding, and electrostatic forces that are present. All of these "constraints" define the nature of the inhibitory compound in terms of structure and functionality; they define the molecular recognition of the RNA by the compound where the compound is complementary in size, shape and chemical surface to the RNA.

As described at pages 19 and 20 of the specification, what was known in the prior art clearly established the importance of hydrogen bonding and hydrophobic interactions in the recognition of specific DNA sequences by proteins such as repressors and endonucleases. Studies such as these have provided the impetus for understanding the helical configuration of RNA, and more specifically, the minor groove. Again, what is critical is the correct spatial arrangement of hydrogen bond donors and acceptors on the inhibitor, as well as the correct geometrical shape as defined by the width, depth, and bonding forces present in the minor groove. The specification defines the forces, as further described above, that establish the structure of the critical region in terms of specific available interactions and geometry. These features are easily obtained upon identifying the RNA sequence to be targeted. Secondary and

U.S.S.N. 08/249,689

Filed: May 26, 1994

DECLARATION UNDER 37 C.F.R. § 1.132

tertiary structures of the targeted RNA can be derived from any number of commercially available programs. Such programs include Macro Model (generation and energy minimization of RNA structures) that was known as of September 1990. There is also MFOLD (prediction of RNA secondary structure by Energy Minimization), RNAfold (calculate secondary structures of RNAs), RNAeval (calculate energy of RNA sequences on given secondary structure), RNAheat (calculate specific heat of RNAs), RNAdistance (calculate distances of RNA secondary structures), RNApdist (calculate distances of thermodynamic RNA secondary structures ensembles), RNAinverse (find RNA sequences with a given secondary structure), RANsubopt (calculate suboptimal secondary structures of RNAs), palindrome (identify inverted repeats in a nucleotide sequence), and RNAGA (predict common secondary structures of RNAs by genetic algorithm).

7. I declare that all statements made herein of my own knowledge and belief are true and that all statements made on information and belief are believed to be true, and further, that the statements are made with the knowledge that willful false statements are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 19 Feb '02

ATL1 #506069 v1

Julius Rotske Jr

JULIUS REBEK, JR.

Director, The Skaggs Institute for Chemical Biology
Professor of Chemistry, Department of Chemistry
The Scripps Research Institute

Biographical Sketch

Julius Rebek, Jr. was born in Hungary in 1944 and lived in Austria from 1945-49. He and his family then settled in the U.S.A. in Kansas. He received his undergraduate education at the University of Kansas in 1966, and obtained the Ph.D. degree from the Massachusetts Institute of Technology (1970) for studies in peptide chemistry with Professor D.S. Kemp. As an Assistant Professor at the University of California at Los Angeles (1970-1976) he developed the three-phase test for reactive intermediates. In 1976 he moved to the University of Pittsburgh where he rose to the rank of Professor of Chemistry and developed cleft-like structures for studies in molecular recognition. In 1989 he returned to the Massachusetts Institute of Technology, where he was the Camille Dreyfus Professor of Chemistry and devised synthetic, self-replicating molecules. In July of 1996, he moved his research group to The Scripps Research Institute to become the Director of The Skaggs Institute for Chemical Biology, where he continues to work in molecular recognition and self-assembling systems.

Biographical Data

Birth date: April 11, 1944; Beregszasz, Hungary

Education: B.A., University of Kansas, 1966
Ph.D., Massachusetts Institute of Technology, 1970

Positions: University of California, Los Angeles
Assistant Professor, 1970-1976

University of Pittsburgh
Associate Professor, 1976-1979
Professor, 1980-1989

Massachusetts Institute of Technology, Cambridge, MA
Professor, 1989-1991
Camille Dreyfus Professor of Chemistry, 1991-1996

The Scripps Research Institute, La Jolla, CA
Director, The Skaggs Institute for Chemical Biology
and Professor of Chemistry, 1996

Honors and Awards

NSF Predoctoral Fellow, 1967-1970
Eli Lilly Award, 1972-1974
A. P. Sloan Fellow, 1976-1978
A. von Humboldt Fellow, 1981
J. S. Guggenheim Fellow, 1986

A.C. Cope Scholar Award, 1991
American Academy of Arts and Sciences, 1993
National Academy of Science, 1994
Highland Park High School Hall of Fame, 1995
NIH Merit Award, 1996
James Flack Norris Award in Physical Organic Chemistry, ACS, 1997
American Association for Advancement of Science Fellow, 2000
Hungarian Academy of Science, 2001

Named Lectureships

Organic Synthesis, Inc. Lecturer, Notre Dame, 1986
J. Clarence Karcher Lecturer, University of Oklahoma, 1988
Frontiers of Science Lectures, Texas A & M University, 1989
Dow Lectures, Michigan State University, 1989
Merck Lecturer, University of Sherbrooke, 1990
Distinguished Lecture Series, University of Florida, 1990
Bender Lectures, Northwestern University, 1990
Abbot Lecturer, Yale University, 1991
H. M. Friedman Lecturer, Rutgers University, 1991
Phillips Lectures, Haverford College, 1991
Special Lecture Series, Scripps Research Institute, 1991
Organic Synthesis, Inc. Lecturer, Colorado State Univ., 1991
MIKI Keynote Lecturer, University of Kansas, 1991
Merck Lecturer, Lehigh University, 1992
Merck Lecturer, University of Montreal, 1992
Franklin Lecturer, University of Kansas, 1992
Bio Mega Lecturer, Montreal, 1993
Miles Lecturer, University of New Hampshire, 1993
Syntex Lecturer, University of Colorado, 1993
Wm. Rauscher Lecturer, Rensselaer Polytechnic, 1993
Seman Lecturer, Kent State University, 1994
Robert Robinson Memorial Lecturer, Oxford, 1994
Welch Foundation Lecturer, Texas Universities, 1994
Linus Pauling Lecturer, Stanford University, 1995
E. K. C. Lee Lecturer, UC Irvine, 1995
Kilpatrick Lecturer, Illinois Institute of Technology, 1996
Lord Lectureship, Allegheny College, 1996
Watkins Lectureship, Wichita State University, 1997
Hirschman Lecturer, Oberlin College, 1998
Oersted Lecturer, Technical University of Denmark at Lyngby, 1998
S.C. Lind Lectureship, University of Tennessee, Knoxville, 1998
Lyle Dawson Lecturer, University of Kentucky, 1998
Reynold Fuson Lectureship, University of Nevada, Reno, 1999
Brantford Chemicals Distinguished Lecturer, Queen's University, Canada, 1999
David Ginsburg Memorial Lecture, Israel Institute of Technology, Israel, 2000
Schlemper Distinguished Lecture in Chemistry, University of Missouri, 2000
Priestley Lecturer, Pennsylvania State University, 2000
Martino Steer Memorial Lecturer, Modena University, Italy, 2000

Johnson Lecturer, Yale University, 2001
Lipscomb Lecturer, University of South Carolina, 2001
Gomberg Lecturer, University of Michigan, 2001
Guthikonda Lecture, Columbia University, 2001
Henry J. Shine Endowment Lecturship, Texas Tech University, 2001
Jack Fox Lecture, Memorial Sloan-Kettering Cancer Center, 2002

Research Interests

Molecular Diversity, Molecular Recognition, Self-Replicating and Self-Assembling Systems.

Editorial Advisory Boards:

Journal of Molecular Recognition, 1987-1995
Chemtracts, 1987-1996
Bioorganic and Medicinal Chemistry Letters, 1991-
Bioorganic and Medicinal Chemistry, 1991-
Journal of the Chemical Society, Perkin Transactions, 1992-
Chemistry and Biology, 1994-
Accounts of Chemical Research, 1996-1998
Journal of Organic Chemistry, 1996-
Current Opinion in Chemistry Biology, 1997-
Tetrahedron Publications, 1991-
Progress in Physical Organic Chemistry, 1998-
Journal of Supramolecular Chemistry, 2001-

Scientific Advisory Boards:

Commercial

Amira (RepliGen), Cambridge, Massachusetts 1990 -1994
Procept, Cambridge, Massachusetts 1991-1997
Darwin Molecular, Seattle, Washington 1992-1995
Cubist Pharmaceuticals, Cambridge, Massachusetts 1992-2001
Discovery Partners International, La Jolla, California, 1996-2001
EPIgen, La Jolla, California, 1996-2001
Synteni (Incyte), Fremont, California, 1997-2001
LaunchCyte, Pittsburgh, PA, 2000-2002
Neogenesis, Cambridge, Massachusetts, 1997-
Personal Chemistry, Uppsala, Sweden, 1999-
Activx, La Jolla, CA, 2001-
Kémia, La Jolla, CA, 2002-

Institutional

University of Chicago, Physical Sciences Division, Chicago, Illinois, 2000-
National Cancer Institute, National Institutes of Health, Bethesda, MD, 2001-
The Institute of Chemical Research of Catalonia, Spain, 2001-
University of Oxford, Elector, Chair in Chemical Biology, 2001-

Publications: Dr. Rebek has published over 300 scientific articles.